Inicio > DIEBOLD LUQUE, MARIA YOLANDA

DIEBOLD LUQUE, MARIA YOLANDA

PROFESORES TITULARES DE UNIVERSIDAD
Cirugía, Oftalmología, Otorrinolaringología y Fisioterapia
GRUPO DE INVESTIGACION EN SUPERFICIE OCULAR (GSO)
 
yol@ioba.med.uva.es
0

Índice H en Web of Science: 22
Índice H en Scopus: 23
 
Enlazar esta página

[][com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53744]], camposKey:0378-5173 2020-01-01 Functional ibuprofen-loaded cationic nanoemulsion: Development and optimization for dry eye disease treatment00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53209]], camposKey:1932-6203 2020-01-01 Histological and immunohistochemical characterization of the porcine ocular surface00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53745]], camposKey:0146-0404 2019-01-01 Morphofunctional study of porcine ocular surface for preclinical research.00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=51255]], camposKey:1090-0535 2019-01-01 Reliability and reproducibility of a rodent model of choroidal neovascularization based on the subretinal injection of polyethylene glycol194203, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=41561]], camposKey:1661-6596 2019-01-01 Topical application of TGF-ß-activating peptide, KRFK, prevents inflammatory manifestations in the TSP-1-deficient mouse model of chronic ocular inflammation00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=46966]], camposKey:2045-2322 2018-01-01 Context-Dependent Regulation of Conjunctival Goblet Cell Function by Allergic Mediators00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=41562]], camposKey:2041-5990 2018-01-01 Cross-linked hyaluronan films loaded with acetazolamide-cyclodextrin-triethanolamine complexes for glaucoma treatment205219, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=41426]], camposKey:0014-4835 2018-01-01 Improved in vitro corneal delivery of a thrombospondin-1-derived peptide using a liposomal formulation118121, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53746]], camposKey:0146-0404 2018-01-01 Melatonin receptors are present in the porcine ocular surface and are involved in ex vivo corneal wound healing00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=41425]], camposKey:1673-5374 2018-01-01 Ocular findings in Zucker Diabetic Fatty rats emphasize the key role of neuroglia degeneration in diabetic retinopathy pathophysiology239240, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=41424]], camposKey:0378-5173 2018-01-01 Sorbitan ester nanoparticles (SENS) as a novel topical ocular drug delivery system: Design, optimization, and in vitro/ex vivo evaluation2030, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=46967]], camposKey:1932-6203 2017-01-01 An engineered human conjunctival-like tissue to study ocular surface inflammatory disease00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53747]], camposKey:0146-0404 2017-01-01 An ex vivo model using porcine eyeballs for wound healing studies00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=41427]], camposKey:0378-5173 2017-01-01 Designing lipid nanoparticles for topical ocular drug delivery204217, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52640]], camposKey:1755-375X 2017-01-01 Effects of plasma kallikrein inhibitors in an in vitro RPE oxidative stress model00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=41428]], camposKey:0146-0404 2017-01-01 Histologic characterization of retina neuroglia modifications in diabetic zucker diabetic fatty rats49254933, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=41429]], camposKey:0014-4835 2017-01-01 Novel anti-inflammatory liposomal formulation for the pre-ocular tear film: In vitro and ex vivo functionality studies in corneal epithelial cells7987, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=41431]], camposKey:1542-2321 2016-01-01 Conjunctival Goblet Cell Function: Effect of Contact Lens Wear and Cytokines8390, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53748]], camposKey:0146-0404 2016-01-01 Functionality of a liposome-based anti-inflammatory formulation in an in vitro corneal inflammation model00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10430]], camposKey:1933-0219 2016-01-01 Interaction of IFN-gamma with cholinergic agonists to modulate rat and human goblet cell function206217, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=41430]], camposKey:0378-5173 2016-01-01 Preliminary characterization of dexamethasone-loaded cross-linked hyaluronic acid films for topical ocular therapy237243, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53749]], camposKey:0146-0404 2015-01-01 An in vitro model using corneal cells to test antiangiogenic activity00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10432]], camposKey:0146-0404 2015-01-01 Comparison of the expression of TGF beta 2activating molecules in conjunctival inflammation00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10436]], camposKey:1080-7683 2015-01-01 Inflammatory Cytokine-Mediated Regulation of Thrombospondin-1 and CD36 in Conjunctival Cells419428, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10418]], camposKey:0146-0404 2015-01-01 Soluble hyaluronan receptor CD44 levels secreted by human conjunctival cells change in inflammatory conditions00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10444]], camposKey:0014-4835 2015-01-01 Thrombospondin-1 induces differential response in human corneal and conjunctival epithelial cells lines under in vitro inflammatory and apoptotic conditions114, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10439]], camposKey:0146-0404 2014-05-01 Trefoil Factor Family Peptide 3 (TFF3) is Upregulated Under Experimental Conditions Similar to Dry Eye Disease and Supports Corneal Wound Healing Effects In Vitro30373042, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=680]], camposKey:0721-832X 2014-01-01 CD44 and RHAMM hyaluronan receptors in human ocular surface inflammation12891295, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10437]], camposKey:0014-4835 2014-01-01 IL-6 as a corneal wound healing mediator in an in vitro scratch assay183192, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10427]], camposKey:0378-5173 2014-01-01 Nanoparticles based on naturally-occurring biopolymers as versatile delivery platforms for delicate bioactive molecules: An application for ocular gene silencing1220, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10442]], camposKey:0962-9351 2014-01-01 Purinergic Receptors in Ocular Inflammation00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=663]], camposKey:0969-7128 2013-01-01 A nanomedicine to treat ocular surface inflammation: performance on an experimental dry eye murine model467477, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10438]], camposKey:0146-0404 2013-01-01 A New Human Primary Epithelial Cell Culture Model to Study Conjunctival Inflammation71437152, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10434]], camposKey:1090-0535 2013-01-01 Involvement of corneal epithelial cells in the Th17 response in an in vitro bacterial inflammation model8599, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10425]], camposKey:0378-5173 2013-01-01 Novel bioadhesive hyaluronan-itaconic acid crosslinked films for ocular therapy4856, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10413]], camposKey:0948-6143 2012-01-01 Hyaluronan receptors in the human ocular surface: a descriptive and comparative study of RHAMM and CD44 in tissues, cell lines and freshly collected samples165176, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10409]], camposKey:0271-3683 2012-01-01 Structural and Functional Alteration of Corneal Epithelial Barrier Under Inflammatory Conditions971981, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=41563]], camposKey:1871-5230 2011-01-01 Drug delivery systems for ophthalmic administration of antiinflammatory agents203214, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10421]], camposKey:1543-8384 2011-01-01 Expression of MUC5AC in Ocular Surface Epithelial Cells Using Cationized Gelatin Nanoparticles17831788, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=757]], camposKey:1090-0535 2011-01-01 Intracellular trafficking of hyaluronic acid-chitosan oligomer-based nanoparticles in cultured human ocular surface cells279290, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=672]], camposKey:1350-9462 2010-11-01 Applications of nanoparticles in ophthalmology596609, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=790]], camposKey:0927-3948 2010-01-01 Dry Eye Disease as an Inflammatory Disorder244253, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10411]], camposKey:1359-6446 2010-01-01 In vitro silencing of TGF beta 1 in a corneal epithelial cell line using nanoparticles10891090, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=760]], camposKey:0277-3740 2010-01-01 Ocular Tolerance to a Topical Formulation of Hyaluronic Acid and Chitosan-Based Nanoparticles550558, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10440]], camposKey:0007-1161 2009-10-01 Branched-chain fatty acids, increased in tears of blepharitis patients, are not toxic for conjunctival cells13911395, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10443]], camposKey:0013-7227 2009-05-01 Somatostatin Actions via Somatostatin Receptors on the Ocular Surface Are Modulated by Inflammatory Processes22542263, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=661]], camposKey:1090-0535 2009-01-01 Characterization and short-term culture of cells recovered from human conjunctival epithelium by minimally invasive means21852195, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=719]], camposKey:1052-2166 2009-01-01 Comparison of Gene Expression Profiles of Conjunctival Cell Lines With Primary Cultured Conjunctival Epithelial Cells and Human Conjunctival Tissue265278, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=310]], camposKey:0271-3683 2009-01-01 Genetically Engineered Elastin-Like Polymer as a Substratum to Culture Cells from the Ocular Surface4856, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=777]], camposKey:1043-4666 2008-01-01 Cytokine responses by conjunctival epithelial cells: An in vitro model of ocular inflammation160167, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10441]], camposKey:0014-4835 2007-03-01 Lymphocytic infiltration and goblet cell marker alteration in the conjunctiva of the MRL/MpJ-Fas(lpr) mouse model of Sjogren's syndrome500512, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=716]], camposKey:0142-9612 2007-01-01 Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP)15531564, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=771]], camposKey:0003-9950 2006-01-01 Altered expression of neurotransmitter receptors and neuromediators in vernal keratoconjunctivitis462468, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=767]], camposKey:0146-0404 2006-01-01 Chitosan nanoparticles as a potential drug delivery system for the ocular surface: Toxicity, uptake mechanism and in vivo tolerance14161425, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=750]], camposKey:0271-3683 2005-01-01 Alpha(2)-Adrenergic receptors are present in normal human conjunctiva11211129, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47233]], camposKey:1573-904X 2005-01-01 Erratum: Chitosan Nanoparticles as New Ocular Drug Delivery Systems: In Vitro Stability, in Vivo Fate, and Cellular Toxicity (Pharmaceutical Research (2004) 21 (803-810))10070, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=754]], camposKey:0146-0404 2005-01-01 Expression of muscarinic and adrenergic receptors in normal human conjunctival epithelium504513, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=56649]], camposKey:0146-0404 2005-01-01 Inflammatory cytokine effects on co-stimulatory molecule and chemokine expression in the human conjunctival epithelial cell line, IOBA-NHC00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=56650]], camposKey:0146-0404 2005-01-01 Ocular surface in vivo tolerance to new nanoparticulate polymer systems designed for drug delivery00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39488]], camposKey:1542-0124 2005-01-01 Variation in the expression of inflammatory markers and neuroreceptors in human conjunctival epithelial cells00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=56651]], camposKey:0146-0404 2004-04-01 Presence of alpha 2-adrenergic receptor subtypes in the normal human conjunctiva.00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10419]], camposKey:0724-8741 2004-01-01 Chitosan Nanoparticles as New Ocular Drug Delivery Systems: in Vitro Stability, in Vivo Fate, and Cellular Toxicity803810, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=778]], camposKey:0014-4835 2004-01-01 Impression cytology of the ocular surface: a review457472, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=56666]], camposKey:0146-0404 2003-05-01 Effect of IFN gamma on muscarinic and adrenergic receptor expression in a normal human conjunctival (NHC) epithelial cell line: Flow cytometry study00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=56668]], camposKey:0146-0404 2003-05-01 Expression of neurotransmitter receptors and Vip in conjunctival biopsies of vernal keratoconjunctivitis patients00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=56664]], camposKey:0146-0404 2003-05-01 In vitro models of ocular inflammation using normal human conjunctival cells00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=56667]], camposKey:0146-0404 2003-05-01 Western blot analysis of muscarinic and adrenergic receptors in a normal human conjunctival (NHC) epithelial cell line00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=758]], camposKey:0146-0404 2003-01-01 Characterization of a spontaneously immortalized cell line (IOBA-NHC) from normal human conjunctiva42634274, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10415]], camposKey:0146-0404 2003-01-01 Uptake of bioadhesive nanoparticles in a normal human conjunctiva (NHC) epithelial cell line00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=56665]], camposKey:0146-0404 2002-05-01 Immunodetection of muscarinic and adrenergic receptors in an epithelial cell line from human conjunctiva00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=762]], camposKey:0146-0404 2002-01-01 Characterization of an epithelial cell line derived from normal human conjunctiva (NHC cell line)00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=744]], camposKey:0146-0404 2002-01-01 Cyclosporin A does not alter the expression of ocular mucin genes in a normal human conjunctival (NHC) cell line00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=740]], camposKey:0065-2598 2002-01-01 Human conjunctival epithelium in culture: A tool to assay new therapeutic strategies for dry eye307311, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10394]], camposKey:0960-8931 2002-01-01 The need for continuous immunosuppression with cyclosporin A to maintain an experimental model of uveal melanoma441447, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=42962]], camposKey:0365-6691 2001-06-01 Cellular biology and ophthalmology Biología celular y oftalmología.337338, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=3563]], camposKey:0365-6691 2001-01-01 In vitro toxicity of non-preserved artificial-tear formulations Lágrimas artificiales sin conservantes: estudio comparativo in vitro.613619, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10414]], camposKey:0146-0404 2000-07-01 Development of conjunctival goblet cells and their neuroreceptor subtype expression21272137, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=41433]], camposKey:0271-3683 2000-01-01 Uveal melanoma model with metastasis in rabbit: Effects of different doses of cyclosporine A740747, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=724]], camposKey:0271-3683 1999-01-01 Ultrastructural evidence of mucus I human conjunctival epithelial cultures95105, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=721]], camposKey:0277-3740 1998-07-01 Carbomer- versus cellulose-based artificial-tear formulations: Morphologic and toxicologic effects on a corneal cell line433440, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=741]], camposKey:1080-7683 1998-01-01 Expression of ICAM-1 and HLA-DR by human conjunctival epithelial cultured cells and modulation by nedocromil sodium517531, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=41436]], camposKey:0146-0404 1997-12-01 Evaluation of chitosan as a substitute for the mucus layer of the preocular tear film00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=720]], camposKey:0721-832X 1997-05-01 Characterization of epithelial primary cultures from human conjunctiva268276, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10426]], camposKey:0146-0404 1997-03-15 Effect of cyclosporine A on the development of experimental choroidal tumors from human uveal melanoma cells in pigmented rabbits37303730, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10422]], camposKey:0146-0404 1997-03-15 The influence of varying blood levels of Cyclosporin A (CsA) in the development of an experimental model of uveal melanoma in albino rabbits37473747, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=41434]], camposKey:0146-0404 1997-01-01 Evidence of mucin production in cultured conjunctival epithelium00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=41435]], camposKey:0146-0404 1997-01-01 In vitro study on the toxic effects of carbomer-derived versus carboxymethylcellulose (CMC)-DERI VED artificial tear formulations upon corneal cells00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=735]], camposKey:0146-0404 1997-01-01 In vitro study on the toxic effects of carbomer-derived versus carboxymethylcellulose (CMC)-derived artificial tear formulations upon corneal cells749749, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10431]], camposKey:0271-3683 1997-01-01 Morphologic and immunocytochemical characterization of four human uveal cell lines (melanoma- and melanocytes-derived)487495, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=41438]], camposKey:0146-0404 1996-01-01 Growth of a human uveal melanoma cell line in rabbits immunosuppressed with different doses of cyclosporin A (CsA)00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=41437]], camposKey:0146-0404 1996-01-01 Nedocromil Sodium (NS) modulates ICAM-1 and HLA-DR expression of human conjunctival epithelial cells in vitro00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=43847]], camposKey:0365-6691 1995-01-01 Caracterización morfológica e inmunocitoquímica de tres líneas celulares de melanoma uveal humano609616, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=41439]], camposKey:0365-6691 1995-01-01 Immunocytochemical and morphological characterization of three uveal melanoma cell lines CARACTERIZACION MORFOLOGICA E INMUNOCITOQUIMICA DE TRES LINEAS CELULARES DE MELANOMA UVEAL HUMANO609616, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39502]], camposKey:0031-6768 1991-07-01 MATERNAL ADRENAL HORMONES AND FETAL LUNG GROWTH IN THE RAT00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=41440]], camposKey:1661-7800 1991-01-01 Effects of maternal bilateral adrenalectomy and betamethasone administration on renal rat encephalic development303313][CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=17067]},camposKey: 43 46 In Vitro Activation of Steroid Receptors in Corneal Epithelial Cells Using a Novel Anti-inflammatory Liposomal Formulation 978-88-7587-710-111TH INTERNATIONAL SYMPOSIUM ON OCULAR PHARMACOLOGY AND THERAPEUTICS (ISOPT CLINICAL) 1 2014-01-01 Medimond, CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=17068]},camposKey: 43 47 In Vitro Corneal Compatibility of Cross-Linked Hyaluronan-Itaconic Acid Films 978-88-7587-645-6INTERNATIONAL SYMPOSIUM ON OCULAR PHARMACOLOGY AND THERAPEUTICS (ISOPT) 1 2012-01-01 Medimond, CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=112]},camposKey: 101 104 Chitosan-Based Colloidal Systems as Promising Topical Drug Carriers for Ocular Surface Disorders 978-88-7587-431-57th International Symposium on Ocular Pharmacology and Therapeutics 1 2008-01-01 Medimond International Proceedings][][][][][][com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=61412]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=61845]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=57459]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=60606]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=61373]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=61406]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=56556]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=56600]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=56537]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=56793]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=56582]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=56922]]][com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=61412]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=61845]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=57459]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=60606]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=61373]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=61406]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=56556]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=56600]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=56537]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=56793]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=56582]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=56922]]][][][com.sigma.fs3.argos.domain.gpc.GpcTesis[id=com.sigma.fs3.argos.domain.gpc.GpcTesisPK[ifcactivitat=TES, ifccomptador=2145638424]], com.sigma.fs3.argos.domain.gpc.GpcTesis[id=com.sigma.fs3.argos.domain.gpc.GpcTesisPK[ifcactivitat=TES, ifccomptador=2145637287]], com.sigma.fs3.argos.domain.gpc.GpcTesis[id=com.sigma.fs3.argos.domain.gpc.GpcTesisPK[ifcactivitat=TES, ifccomptador=2145636903]], com.sigma.fs3.argos.domain.gpc.GpcTesis[id=com.sigma.fs3.argos.domain.gpc.GpcTesisPK[ifcactivitat=TES, ifccomptador=2145637004]], com.sigma.fs3.argos.domain.gpc.GpcTesis[id=com.sigma.fs3.argos.domain.gpc.GpcTesisPK[ifcactivitat=TES, ifccomptador=2145631907]]][][][][][][][][com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@33e888b0, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@6765f56f, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@56d47f71, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@18fb0040][][com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@3751d0, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@3da4a0, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@372680, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@372d14, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@372be2, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@372be1, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@372619, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@3da496, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@3da1c9, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@3da190, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@3da49c, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@3da494, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@3d9400, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@3da49d, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@3d9e5f, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@37522f, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@373be0, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@373b9f, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@3730d4][][][com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.gpc.GpcEstadesForaPK[ifcactivitat=ESF, ifccomptador=59153]], com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.gpc.GpcEstadesForaPK[ifcactivitat=ESF, ifccomptador=56749]], com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.gpc.GpcEstadesForaPK[ifcactivitat=ESF, ifccomptador=56536]], com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.gpc.GpcEstadesForaPK[ifcactivitat=ESF, ifccomptador=56523]], com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.gpc.GpcEstadesForaPK[ifcactivitat=ESF, ifccomptador=59638]]][com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.gpc.GpcEstadesForaPK[ifcactivitat=ESF, ifccomptador=59153]], com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.gpc.GpcEstadesForaPK[ifcactivitat=ESF, ifccomptador=56749]], com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.gpc.GpcEstadesForaPK[ifcactivitat=ESF, ifccomptador=56536]], com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.gpc.GpcEstadesForaPK[ifcactivitat=ESF, ifccomptador=56523]], com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.gpc.GpcEstadesForaPK[ifcactivitat=ESF, ifccomptador=59638]]][][com.sigma.fs3.argos.domain.gpc.GpcPatents[id=com.sigma.fs3.argos.domain.gpc.GpcPatentsPK[ifcactivitat=PAT, ifccomptador=1172]]][][com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@45f95c], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@414e9e], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@45fb2c], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@41337f], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@46340d], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@41261d], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@412553], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@41377d], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@413bdc], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@4125d5], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@412448], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@41286d], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@412437], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@4123c6], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@412123], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@4122a5], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@4120cf], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@411f50], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@411db1], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@411b70], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@460477], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@411ead], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@411c9f], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@45f38a], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@45f373], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@45f375]][][][com.sigma.fs3.argos.domain.gpc.altres.ProjecteInnovacio@156aa, com.sigma.fs3.argos.domain.gpc.altres.ProjecteInnovacio@155c6][]

PUBLICACIONES

Artículos de revista (95)

Jurisic Dukovski, B. ; Juretic, M. ; Bracko, D. ; Randjelovic, D. ; Savic, S. ; Crespo Moral, M. ; Diebold, Y. ; Filipovic-Grcic, J. ; Pepic, I. ; Lovric, J. Functional ibuprofen-loaded cationic nanoemulsion: Development and optimization for dry eye disease treatment . INTERNATIONAL JOURNAL OF PHARMACEUTICS 2020; 576.

Enlace a la publicación
Ver Todos

Capítulos de libros (3)

Soriano-Romani, L.; Vicario-De-La-Torre, M.; López-García, A.; Molina-Martínez, I.T .; Herrero-Vanrell, R.; Diebold, Y. In Vitro Activation of Steroid Receptors in Corneal Epithelial Cells Using a Novel Anti-inflammatory Liposomal Formulation. En: Medimond. 11TH INTERNATIONAL SYMPOSIUM ON OCULAR PHARMACOLOGY AND THERAPEUTICS (ISOPT CLINICAL). Medimond; 2014. p. 43-46


Ver Todos
 

AYUDA A LA INVESTIGACIÓN

Proyectos (26)

DELIVERY DE EXOSOMAS ARTIFICIALES PARA EL TRATAMIENTO DE ENFERMEDADES OCULARES CONDUCENTES A LACEGUERA (ARTEX4EYE). Equipo Investigadores: GARCIA POSADAS, LAURA (IP); DIEBOLD LUQUE, MARIA YOLANDA (IP); USSA HERRERA, FERNANDO. Personal Contratado: ALONSO ALONSO, MARIA LUZ. RTI2018-094071-B-C21. Entidades Participantes: UNIVERSIDAD DE VALLADOLID (UVa). Entidades Financiadoras: AGENCIA ESTATAL DE INVESTIGACIÓN, FONDOS FEDER. 2019-01-01 - 2022-12-31
Ver Todos

Convenios (19)

DESARROLLO DE UNA PLATAFORMA DE EVALUACIÓN PRECLÍNICA DE FÁRMACOS EN PATOLOGÍA DE SUPERFICIE OCULAR. Equipo Investigadores: CALONGE CANO, MARGARITA (IP); SOBAS ABAD, EVA MARIA; LOPEZ PANIAGUA, MARINA; ENRIQUEZ DE SALAMANCA Y ALADRO, AMALIA; HERRERAS CANTALAPIEDRA, JOSE MARIA; GALINDO DE LA ROSA, SARA; VAZQUEZ HERNANDEZ, AMANDA; MARTINEZ PLAZA, ELENA; GARCIA VAZQUEZ, MARIA DEL CARMEN; DIEBOLD LUQUE, MARIA YOLANDA; NIETO MIGUEL, TERESA. Entidades Financiadoras: UNIVERSIDAD DE VALLADOLID (UVa).. 2019-01-01
Ver Todos

Otras ayudas y becas (12)

CONTRATO PREDOCTORAL MINECO (FPI) DE ISMAEL ROMERO CASTILLO: "Desarrollo de exosomas artificiales y su combinación con andamiajes bioinspirados para el tratamiento de enfermedades inflamatorias de la superficie ocular". DIEBOLD LUQUE, MARIA YOLANDA (Director). ROMERO CASTILLO, ISMAEL (Beneficiario). 01/11/2020 - 2024-10-31. 92.750,00 EUR.
Ver Todos
 

OTROS

Tesis doctorales (5)


Texto completo en acceso abierto  
Ver Todos

Congresos (4)

ASISTENCIA: ARVO, VANCOUVER ( CANADÁ ) 28/04/2019 -
(Conferencia invitada). DIEBOLD LUQUE, MARIA YOLANDA. ASISTENCIA: ARVO
Ver Todos

Patentes (1)

Yolanda Diebold. Nanopartículas para la prevención y/o tratamioento de enfermedades de mucosas. P-201031678/PCT/ES2011070780. 2017
Ver Todos

Estancias de investigación (5)

AYUDAS UVA A LA INVESTIGACION: ESTANCIA DE INVESTIGACION : UNIVERSIDAD HARVARD. 06/05/2010 - 21/05/2010
     HARVARD UNIVERSITY. BOSTON ( ESTADOS UNIDOS DE AMÉRICA )
Ver Todos
Cargando información ...
Universidad de Valladolid - Copyright Universidad de Valladolid - Todos los derechos reservados